FDC Limited’s board has approved an interim dividend of ₹5 per equity share for FY 2025-26, with February 11, 2026, set as the record date. The board also reviewed and approved the unaudited standalone and consolidated financial results for Q3 (Oct-Dec) and nine months ended December 31, 2025.
Interim Dividend Declared
The Board of Directors has approved an interim dividend of ₹5 per equity share (face value of ₹1 each) for the financial year 2025-26. The record date for determining eligible shareholders has been fixed as Wednesday, February 11, 2026. This decision, made during a meeting held on February 5, 2026, reflects the company’s commitment to rewarding its investors.
Financial Performance: Q3 & Nine Months
The Board also reviewed and approved the unaudited standalone and consolidated financial results for Q3 (Oct-Dec) and the nine-month period ending December 31, 2025.
Standalone Results (₹ in lakhs):
- Total Income: ₹48,001.02 for Q3 (Oct-Dec), ₹163,909.73 for nine months ended December 31, 2025.
- Profit Before Tax: ₹3,502.21 for Q3 (Oct-Dec), ₹23,539.86 for nine months ended December 31, 2025.
- Net Profit After Tax: ₹2,718.71 for Q3 (Oct-Dec), ₹17,885.31 for nine months ended December 31, 2025.
Consolidated Results (₹ in lakhs):
- Total Income: ₹48,550.59 for Q3 (Oct-Dec), ₹166,307.11 for nine months ended December 31, 2025.
- Profit Before Tax: ₹3,638.41 for Q3 (Oct-Dec), ₹23,424.82 for nine months ended December 31, 2025.
- Net Profit After Tax: ₹2,830.26 for Q3 (Oct-Dec), ₹17,802.49 for nine months ended December 31, 2025.
Impact of New Labour Codes
FDC Limited recognized estimated obligations of ₹2,078.91 lakhs due to changes in the New Labour Codes as an exceptional item. The impact was assessed based on actuarial valuation in accordance with Ind AS 19 and disclosed as non-recurring in nature.
Segment Information
The company operates within a single segment, which is the “Pharmaceuticals” sector.
Source: BSE
